Measurement of Relaxin Peptide in Multiple Sclerosis (MS)

N/ACompletedNCT01909492

Providence Health & Services30 enrolled

Overview

This study will evaluate relaxin (RLX) levels in patients with multiple sclerosis.

The goal of this study is to obtain baseline information on serum and cerebrospinal fluid (CSF) relaxin levels in patients with MS, as well as to further study RXFP-1 receptor binding affinity for RLX in patients with active and clinically stable MS.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

Blood DrawPROCEDURE

Patients will provide a serum sample for research.

Lumbar PuncturePROCEDURE

Patients will have a lumbar puncture to obtain CSF.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with suspected MS, who have had a clinical attack within the last 12 weeks, have at least one gadolinium-enhancing lesion on brain or spinal cord MRI taken within the prior 4 weeks, and for which they have not received any immunomodulating or immunosuppressant medication. * Subjects with clinically stable definite MS, with no evidence of clinical relapse for at least the past 12 weeks, and have no gadolinium enhancing lesions on MRI in the prior 4 weeks. These subjects will fulfill the Revised (2010) McDonald's Criteria for the Diagnosis of MS. * Subjects without evidence of inflammatory systemic or inflammatory central nervous system disease, who require CSF removal for some other cause, such treatment of benign intracranial hypertension or as part of the procedure for insertion of an intrathecal medication delivery system. Exclusion Criteria: \- Pregnancy

Locations (1)

Providence MS Center

Portland, Oregon, United States

Outcomes

Primary Outcomes

Relaxin (RLX) Levels

There is no information available on what serum and CSF levels of RLX are observed in patients with active versus stable relapsing MS, how these values compare to that found in human volunteers without MS or other inflammatory diseases, and whether RLX functions normally in subjects with active or stable MS. RLX2 concentrations were expressed as picomoles per milliliter (pmol/mL) of serum or CSF.

Time frame: During diagnostic LP

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.